Tandem Diabetes (NASDAQ: TNDM) today announced the commercial launch of the newest version of its flagship insulin pump in the U.S. market. The company's signature t:slim X2 insulin pump will also now come with Control-IQ technology, which is meant to help stabilize blood sugar levels via an automated insulin dosing system.
Insulin pumps are a type of insulin delivery device that simulate the way the pancreas works by delivering small doses of insulin throughout the body. Tandem's main product is its t:slim X2 pump, one of the top insulin pumps in the market right now, with sales having seen dramatic growth over the past couple of years.
An insulin pump. Image source: Getty Images.
"Control-IQ technology has been described by study participants and investigators as 'life-changing,' 'easy to use,' and 'a new standard of care in insulin therapy management'," said Tandem CEO John Sheridan. This technology, which will be made available to existing t:slim users via a software update, is only compatible with one other insulin monitoring system out there, Dexcom's G6 continuous glucose monitoring tool (the G6, however, is not an insulin pump).
Potential competitors on the horizon
The Food and Drug Administration approved Tandem's Control-IQ platform back in December, and now that it's officially hitting the market, investors are excited to see how this will change Tandem's sales figures.
But there still are some serious biotech competitors that could pose a threat to Tandem's position in the market. The most notable is Insulet (NASDAQ: PODD), which is developing its own insulin pump, the Omnipod Horizon, that should be available sometime in late 2020. It's quite likely that Insulet's new pump will siphon off market share from Tandem.
10 stocks we like better than Tandem Diabetes Care
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Tandem Diabetes Care wasn't one of them! That's right -- they think these 10 stocks are even better buys.
*Stock Advisor returns as of December 1, 2019
Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool recommends Insulet. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
